Marieke Kruidering-Hall PhD

• Academy Chair in Pharmacology Education
• Associate Professor, Department of Cellular and Molecular Pharmacology
• University of California, San Francisco

http://cmp.ucsf.edu/faculty/marieke-kruidering-hall

They then remain infective throughout adult life arteria bologna inderal 80 mg amex, which is usually only a few weeks pulse pressure heart failure order 40 mg inderal otc. Leishmania-infected sandflies have abnormal feeding behavior hypertension vasoconstriction purchase cheap inderal on-line, with increased probing while attempting to take a blood meal arteria genus buy discount inderal 40 mg on line. This behavior may facilitate transmission to the vertebrate host blood pressure heart rate discount 80 mg inderal otc, as well as lead to a chain of skin lesions. Immunologic diagnosis refers to the detection of an antibody or delayed-type hypersensitivity/interferon-gamma release assay response in the host to Leishmania antigens. It is important to note there is not a single diagnostic test that is optimal in all clinical settings. It is always preferable to perform more than one parasitologic assay when possible. Each geographic region has a unique combination of parasite strains, sandfly vectors, mammalian reservoirs, and human hosts of different genetic backgrounds. A treatment regimen that is efficacious in one area may not be efficacious in another. Clinical cure is the resolution of the signs and symptoms of disease within a defined period. Final clinical cure is achieved with no recurrence of symptoms (no relapse) at 6 months. Parasitologic cure refers to the eradication of Leishmania parasites, which occurs infrequently; infection is usually life-long. Parasitologic response is often defined as the decrease or absence of parasites by smear or culture within a defined period after treatment. For example, a splenic aspiration may be 3+ before therapy and smear-negative at the end of therapy, indicating a parasitologic response. Parasitologic response end points are utilized in research studies to assess response to treatment but are not commonly used or recommended in routine clinical care. Persistence of Viable Parasites Successful chemotherapy leading to clinical cure does not eradicate parasites from the host. A historical overview of the classification, evolution, and dispersion of Leishmania parasites and sandflies. Quantification of the infectious dose of Leishmania major transmitted to the skin by single sand flies. The sand fly salivary protein lufaxin inhibits the early steps of the alternative pathway of complement by direct binding to the proconvertase C3b-B. Immunity to distinct sand fly salivary proteins primes the anti-Leishmania immune response towards protection or exacerbation of disease. The profound effect of sand fly saliva on host hemostasis, inflammation and immunity. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the global burden of disease study 2016. Global leishmaniasis update, 2006-2015: a turning point in leishmaniasis surveillance. Persistence of Leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. Congenital transmission of visceral leishmaniasis (kala azar) from an asymptomatic mother to her child. Molecular tools for diagnosis of visceral leishmaniasis: systematic review and meta-analysis of diagnostic test accuracy. The disease is also known as Kala-azar (Hindi for black fever) because some patients show hyperpigmentation of the skin of the hands, feet, face, or abdomen. Regional epidemiology depends on the interaction of sandflies, reservoir hosts, and susceptible humans. Population movements of nonimmune individuals into endemic areas can result in epidemics. Reservoir Hosts In India, where the domesticated sandfly vector Phlebotomus argentipes feeds solely on humans, people appear to be the only reservoir. Recent studies in Brazil suggest that asymptomatically infected persons can transmit L. Jackals are probably an important source of the sporadic, mainly rural, cases that occur in the Middle East and central Asia. The difference between asymptomatic infection and oligosymptomatic disease is difficult to establish in most endemic areas, because the etiology of non-specific illness is rarely diagnosed and does not warrant evaluation in the context of the culture and health care infrastructure. For example, in a prospective study in Brazil, 28 out of 86 children with antibodies to L. Twenty others remained asymptomatic during observation for up to 5 years, and 38 had a prolonged "sub-clinical" illness manifested by mild constitutional symptoms and intermittent hepatomegaly that resolved without anti-leishmanial treatment after an average of 35 months. In sub-clinical cases or in lymphatic leishmaniasis, there are non-caseating granulomas and giant cell reaction. The skin may contain Leishmania and, in fatal cases, all levels beneath the epidermis are often heavily infiltrated, with masses of parasitized cells concentrated around the sweat glands and arterioles. Therefore "viscerotropic" leishmaniasis should be considered in individuals with unexplained constitutional complaints in endemic areas or in travelers with a history of exposure. Symptoms of Kala-Azar the incubation period is generally 2 to 6 months, although disease occasionally occurs many years after the patient has left an endemic area. The onset of the disease in immunologically naïve adults (migrants, soldiers, and visitors to an endemic area) may be acute in onset with high fever, chills, and malaise. In endemic areas, the disease progression is described as more gradual, with chronic intermittent fever, progressive enlargement of the spleen and liver, and vague abdominal discomfort. Other common symptoms include weight loss, epistaxis, diarrhea, and non-productive cough. Fever is common, classically described as double quotidian, but can be intermittent or constant. Immunocompromised hosts often present with gastrointestinal involvement, mucosal lesions, or disseminated skin lesions. Lesions appear as nodules or ulcers of the gum, palate, tongue, lip, or nasal septum perforation. Mucosal lesions respond to therapy and may be caused by an exaggerated, nonhealing immune response. Leishmania infection is a treatable cause of secondary hematophagocytic syndrome, especially in children. Cancrum oris, a necrotizing oral infection, occurs late in the course when neutropenia is severe. Patients present with deteriorating visual acuity-slit lamp examination shows irregular nodules in the iris. Other rare ocular complications reported are retinal hemorrhages, keratitis, central retinal vein thrombosis, papillitis, and iritis. Laboratory Abnormalities Hematologic Hemoglobin concentrations of 5 to 9 g/dL, white blood cell counts of 2000 to 4000/mm3, and platelet counts of 50,000 to 200,000/ mm3 are typical, although much lower counts are sometimes seen in advanced disease. The prothrombin time is usually 2 to 4 seconds longer than that in controls, and serum albumin is generally less than 3 g/dL. A polyclonal hypergammaglobulinemia of 5 to 10 g/dL, most of which is IgG, is usual. Renal findings may be normal, but concentration defects, red and white blood cells in the urine, proteinuria, and decreased glomerular filtration rate have been reported. Co-infected patients may have atypical presentations that include a variety of pulmonary syndromes. The parasite burden tends to be higher, and serologic tests may be negative; therefore classic parasitologic methods are preferable. Unexplained fever, splenomegaly, and cytopenias in an immunocompromised patient with an appropriate exposure history should prompt consideration of leishmaniasis. A confirmatory parasitologic diagnosis is preferable before starting treatment; in settings where safely performing an invasive procedure is difficult, a presumptive diagnosis can be made using a serologic test (such as rK39 immunochromatographic test) and assessing whether clinical improvement in response to appropriate therapy is seen within a week or so. Initially, they appear as small hypopigmented patches, which enlarge and may progress to nodules that sometimes resemble leprosy. Histologically, there is a spectrum of cellular responses, varying from numerous parasites with few inflammatory cells to a granulomatous reaction containing few parasites. In experienced hands, the procedure is safe and well tolerated; however, deaths have occurred after splenic aspiration in 1: 100 procedures, presumably due to splenic laceration-careful observation after the procedure is mandatory. Splenic smears are often quantitated by the method of Chulay to assist in response to therapy. Amastigotes are also frequently found in aspirates or biopsies of liver specimens or lymph nodes. Hyper-reactive malaria splenomegaly (tropical splenomegaly syndrome) is especially difficult to differentiate, although high titers of anti-malarial antibodies and a characteristic histologic appearance of the liver suggest it. Antimicrobial agents are given when concurrent pneumonia, tuberculosis, or other bacterial infections are suspected. Patients with chronic disease generally tolerate anemia well, but blood transfusion may be needed if associated with respiratory distress or the hemoglobin level falls below 6 g/dL. Sensitivity and specificity vary based on the antigens used in the assay and the infecting parasites. Whole promastigotes, crude promastigote lysates, and recombinant antigens are in use. False-positive results, especially with lower titers, can be seen in malaria, trypanosomiasis, tuberculosis, enteric fever, and schistosomiasis. In East Africa lower sensitivities of 75% to 92% were noted; another recombinant antigen, rK28, showed improved sensitivity. The rK39 test is not useful in screening asymptomatic individuals for infection but should be used in individuals with a compatible clinical syndrome. There is variation in the total antimony (Sb) content, the proportion of SbV to trivalent Sb (trivalent Sb is more toxic than SbV), and the physical and chemical characteristics of different lots of SbV from the same manufacturer and between preparations from different manufacturers. In addition, SbV dissociates or polymerizes over time, so storage conditions and shelf-life are important considerations. Undiluted intravenous injections are not recommended; the daily dose can be given as a 1: 10 dilution with 5% D/W (dextrose water) to reduce the incidence of local thrombosis. In endemic areas, the intramuscular route of administration is more common, although the large-volume injections are moderately painful. Shortly after beginning therapy, patients treated with SbV preparations develop elevations in serum lipase greater than amylase, which peak at 7 to 14 days. Although most are asymptomatic, some develop anorexia, nausea, and mid-epigastric pain consistent with clinical pancreatitis. Deaths attributed to pancreatic necrosis have been reported in patients receiving SbV;44 therefore monitoring of serum amylase and lipase is recommended. Anemia, neutropenia, and thrombocytopenia are occasionally severe enough to interrupt SbV therapy; abnormalities reverse on discontinuation of the drug. Increases in serum transaminases are also seen in the majority of patients during treatment. The optimal agent has not been defined, but L-amB 3 mg/kg every 3 weeks, pentamidine 4 mg salt/kg every 2 weeks, or 20 mg SbV/kg every 3 weeks has been used. Occasional elevated hepatic enzyme concentrations and rare renal toxicity and tetany have been reported. It commonly induces gastrointestinal side effects such as anorexia, nausea, vomiting (38%), and diarrhea (20%). Skin allergy, elevated hepatic transaminase concentrations, and, rarely, renal insufficiency may be observed. Miltefosine is potentially teratogenic and should not be used by pregnant women or women with child-bearing potential for whom adequate contraception cannot be assured for the duration of treatment and for 5 months afterward. One regimen is 1 mg/ kg administered by slow intravenous infusion over 4 to 6 hours every 1 to 2 days, until a total dose of about 20 mg/kg has been given. Sudden cardiac death has been reported after the first dose of amphotericin B deoxycholate in patients who have recently received SbV. Lipid-associated amphotericin B-less toxic and more effective preparations-were introduced in the mid-1990s. The overall success rate with this dose regimen is >90%, except in East Africa, where higher Combination Treatment Combination treatment has the potential advantages of shortening the duration of treatment, reducing the overall dose of medicines, and reducing the probability of selection of drug-resistant parasites, which will improve compliance, reduce drug toxicities, lower costs, and prolong the effective life of the available medicines. In East Africa, the combination of sodium stibogluconate at 20 mg SbV/ kg plus paromomycin given at 15 mg/kg (11-mg base) for 17 days showed an efficacy of 86% to 93%. Relapses are most common during the first 2 to 6 months after finishing treatment; occasionally they occur several years later, particularly in patients who become immunocompromised by disease or medication. Patients who fail to respond or relapse after initial therapy should be treated with a different drug regimen. Additional doses or higher doses of the same regimen could be tried, but only under close supervision. In contrast, the established syndrome of Kala-azar is almost always fatal (90%) in the absence of specific chemotherapy. When humans are the reservoir (India and perhaps parts of East Africa), aggressive case management may help interrupt transmission. For transfusion-associated infection, leukodepletion effectively reduces transmission risk. In Bangladesh, India, and Nepal either an extended regimen of amphotericin B deoxycholate at 1 mg/kg per day by infusion (20 days on, 20 days off), up to 60 to 80 doses over 4 months or miltefosine orally at 50 mg three times daily for 60 days or twice daily for 90 days for 12 weeks is recommended. Shorter course L-amB administered as five biweekly 3-mg/ kg doses (total 15 mg/kg) in Bangladesh was associated with 78% complete cure. Transmission among dogs can be maintained by non-sandfly routes, such as congenital and sexual transmission, as well as between dogs by sandfly transmission.

For the first time blood pressure normal buy inderal 80 mg mastercard, African trypanosomiasis blood pressure chart stroke buy inderal 40 mg with visa, at least in its early stages pulse pressure 49 inderal 80 mg buy cheap, became treatable heart attack high blood pressure order inderal on line. Although life-threatening reactions like anaphylactic shock have been described pulse pressure below 20 order discount inderal line, serious adverse effects are rare. It is given by slow intravenous injection; extravascular leakage must be avoided because of the risk of tissue necrosis. The most important adverse effect is an acute encephalopathy, usually appearing around day 5 to 8 of the treatment course in 5% to 14% of all patients. Severe headache, convulsions, rapid neurologic deterioration, or deepening of coma are the indicators of a reaction, which is immune-mediated by release of parasite antigens in the first days of treatment. The overall case fatality under treatment ranges between 2% and 12%, depending on the stage of disease and the quality of medical and nursing care. Cost and limited availability have restricted its use mostly to melarsoprol-refractory cases of T. Eflornithine can be taken orally, but intravenous administration is preferred, as it achieves a much higher bioavailability and success rate. The agreement has been extended, and there are promising signs for its continuation. Infested strips of land are often well known to the local population and should be avoided as much as possible. Control programs are based on a combination of treatment of patients, mass screening, and vector control, usually by trapping and insecticide spraying. As Glossina is a relatively incompetent vector and susceptible to control measures such as insecticide application or trapping, the combination of various approaches can lead to a complete interruption of transmission. It has a place as a second-line treatment in melarsoprol-refractory cases and especially as a partner in combination therapies. Nifurtimox is often not well tolerated, with gastrointestinal (nausea, epigastric pain) and neurologic (polyneuropathies, ataxia) symptoms being the most pronounced, but adverse effects are usually not severe. Therefore by reducing the overall dosage of each individual component, drug combinations could reduce the frequency of serious adverse effects as well as the selection for resistance. Based on this concept, important progress was made in 2009 by a multi-center trial testing a combination of nifurtimox and eflornithine. New Drug Developments Drugs with fewer adverse effects, better applicability, and reliable availability are urgently needed and have been identified as a priority for research and development in tropical medicine. Insect repellents are only of limited use, as tsetse flies are visually attracted to their prey. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. The atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Magnetic resonance imaging findings in human African trypanosomiasis: a four year follow-up study in a patient and review of the literature. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. In Latin America, Chagas disease affects millions and is one of the leading causes of cardiomyopathy with high morbidity and mortality rates. However, imported Chagas disease is increasingly recognized as an emerging problem in the United States and Europe as a result of immigration from Latin America. Clinicians in non-endemic areas may therefore face migrants with symptomatic or asymptomatic T. Chagas disease is considered a neglected tropical disease, characterized by an urgent need for new tools for screening, treatment, and test of cure. Twenty-eight million people are at risk; it is estimated that 6 million people are currently infected. An estimated 20% to 30% of people who initially have the indeterminate (asymptomatic) form progress over a period of years to clinically evident cardiac and/or gastrointestinal disease. Triatomines of both sexes must take blood meals to develop through their nymphal stages to adults; females require a blood meal to lay eggs. There are at least 130 triatomine species in the Americas; a handful of highly domiciliated vector species are of disproportionate importance in the human epidemiology of disease. Most domesticated species feed nocturnally and are able to complete their blood meal without waking the host. The major Latin American vectors defecate during, or immediately after taking, a blood meal, increasing the likelihood of infecting the host. Some triatomine species can infest both domestic and sylvatic sites and may play a bridging role. More than 100 species of mammals have been reported to have natural infections with T. Sylvatic transmission cycles are maintained by wild mammals and triatomine species; the vectors often colonize nests of rodent or marsupial reservoir hosts. Wild triatomine adults may fly into human dwellings, attracted by light, and cause sporadic human infections. Domestic transmission cycles occur where vectors are adapted to living in human houses and nearby animal enclosures. The peridomestic environment provides abundant hosts that act as blood meal sources, and poor-quality housing provides crevices and other diurnal hiding places for triatomines. An estimated 5% to 6% (range 1%­10%) of infants of infected mothers are born with congenital T. T wenty instances of transmission by organ transplantation have been documented in the literature to date (12 kidney, 1 kidney and pancreas, 3 liver, 1 bilateral lung, 3 heart). Because the infection is lifelong, the seroprevalence in an area with sustained vector-borne transmission rises with age and may reach high levels in adulthood, reflecting cumulative incidence. However, vector-borne transmission occurred historically throughout the Americas from the southern United States to Chile and Argentina. Several Chagas disease control initiatives have made major advances in decreasing house infestation and ensuring T. The major aims are to control transmission by domestic vectors through house spraying programs and to prevent bloodborne T. The Southern Cone Initiative, the first program to be established, has resulted in the certification of elimination of domestic transmission by T. The residual risk in Latin America where screening has been implemented is estimated to be 1: 200,000 units. Congenital Chagas disease screening programs usually rely on prenatal serologic screening followed by microscopic examination of concentrated cord blood from infants of seropositive mothers. These programs have been challenged by suboptimal sensitivity of cord blood screening and high loss to follow-up later in infancy. Triatomine vectors are infected by ingestion Triatomine bug takes a blood meal (passes metacyclic trypomastigotes in feces, trypomastigotes enter bite wound or mucosal membranes, such as the conjunctiva) Metacyclic trypomastigotes penetrate various nucleated cells at bite wound site. Triatomine bug stages Human stages Amastigotes multiply by binary fission in cells of infected tissues Trypomastigotes can infect other cells and transform into intracellular amastigotes in new infection sites. In the triatomine midgut, trypomastigotes transform into epimastigotes, which replicate by binary fission. Daughter epimastigotes migrate to the vector hindgut and differentiate into metacyclic trypomastigotes. Infective metacyclic trypomastigotes are excreted during defecation and enter the mammalian host by penetrating the bite wound or other breaks in the skin, or through intact mucous membranes. Trypomastigotes circulate in blood, invade cells and differentiate into amastigotes which replicate, and then transform into trypomastigotes. The pathogenesis of Chagas disease is incompletely understood; possible factors that may alter chronic severity include the parasite burden and severity of the initial infection, re-infections, the host immune response, and human genetic factors. The occurrence of the digestive form of Chagas disease principally in areas south of the Amazon basin is believed to be a result of differences in parasite strains. Parasite molecules such as cruzipain and transsialidases regulate adhesion and invasion of host cells and/or immune evasion; variations in expression of these molecules may influence the virulence of T. Histopathology reveals localized inflammatory reactions, acute diffuse myocarditis with myocyte necrosis, interstitial edema, and inflammatory cell infiltrates. However, in the absence of effective treatment, tissue infection persists for the life of the host, and a failure to down-regulate the inflammatory response appears to play a role, especially in the pathogenesis of cardiomyopathy. In the indeterminate form of the chronic phase, isolated inflammatory foci may be found in tissues. The parasite may be difficult to detect in the chronic phase, but there is consensus that parasite persistence is required for development of disease. At least four mechanisms are believed to be involved in the pathogenesis of chronic Chagas disease, including parasite-dependent injury, immune-mediated tissue damage, and neurogenic and microvascular changes. Gastrointestinal involvement in chronic Chagas disease is thought to be produced by destruction of autonomic ganglia in the gut walls, with unmasking as a result of age-related attrition of the remaining nerve cells and eventually leading to megaesophagus and/or megacolon. Mostpatientsareasymptomaticor have mild, non-specific symptoms, such as fever, lymphadenopathy, and/or hepatosplenomegaly, and do not come to clinical attention during the acute phase. Some patients have inflammation and swelling at the site of inoculation, known as a chagoma. The parasites in the nest at the bottom of the image are in the process of transforming into trypomastigotes. This is frequently seen in acute cases and is presumed to mark the point of entry of the parasite. Severe acute disease occurs in less than 1% of patients; manifestations include acute myocarditis, pericardial effusion, and/or meningoencephalitis. Acute Chagas disease carries an estimated risk of mortality in the range of 1 in 200 to 1 in 400 cases, but this is difficult to estimate as the vast majority of infections are not detected in the acute phase. Chronic Trypanosoma cruzi Infection Eight to 12 weeks after infection, parasitemia levels become undetectable by microscopy and, in the absence of effective antitrypanosomal treatment, the individual passes into the chronic phase of T. Despite the absence of microscopically detectable parasites in the peripheral blood, persons with chronic T. An estimated 20% to 30% of people who initially have the indeterminate form progress over a period of years (to decades) to clinically evident cardiac and/or gastrointestinal disease. This form is more frequently seen in patients infected in the countries of the Southern Cone, and is rare in northern South America, Central America, and Mexico. The effects on the esophagus span a spectrum from asymptomatic motility disorders through mild achalasia to severe megaesophagus. Symptoms include dysphagia, odynophagia, esophageal reflux, weight loss, aspiration, cough, and regurgitation. As noted in the section on non-vectorial transmission, available data suggest that transmission occurs in a minority of recipients of solid organs from T. In a patient series in Argentina, 3 (19%) of 16 recipients of kidney transplants from infected donors acquired T. A similar transmission rate (2/11, 18%) was reported in kidney recipients in the United States. Based on these data, transplantation of kidneys from known infected donors may be considered with appropriate informed consent and post-transplantation monitoring. Severely affected neonates may have myocarditis, meningoencephalitis, gastrointestinal megasyndromes, anasarca, pneumonitis, and/or respiratory distress. In published studies from the 1990s and earlier, mortality among infected infants was significantly higher than in uninfected infants, ranging from <5% to 20%. More recent cohort studies have shown lower rates of severe congenital Chagas disease, and some investigators hypothesize that disease severity has decreased as a result of better vector control and decreasing maternal parasite exposure. Reactivation of Chronic Trypanosoma cruzi Infection in Organ Recipients Patients with chronic T. Survival of patients who received a heart transplant because of chronic Chagas cardiomyopathy was better than among those with idiopathic or ischemic cardiomyopathy; T. Reactivation was diagnosed at times varying from 38 days to more than 7 years after transplantation. In addition to fever and acute Chagas myocarditis in the transplanted heart, common manifestations of reactivation disease include inflammatory panniculitis and skin nodules. Reactivation should be considered in the differential diagnosis of febrile episodes and apparent rejection crises. Trypanosoma cruzi Infection in the Immunocompromised Host Acute Trypanosoma cruzi Infection in Organ Transplantation Recipients Acute T. The second most commonly reported sign is acute myocarditis, sometimes superimposed on pre-existing chronic Chagas cardiomyopathy. Patients may present with new arrhythmias, pericardial effusion, acute cardiac decompensation, or accelerated progression of chronic heart disease. The management of a blood donor with reported positive results by blood bank screening assays should begin with confirmation by at least two serologic tests conducted by a diagnostic laboratory. Patients with confirmed infection should be counseled not to donate blood in the future, and testing should be offered to family members with likely exposure to vectorial transmission and children of T. No single serologic assay has sufficient sensitivity and specificity to be relied on alone; two tests based on different antigens. The status of some individuals remains difficult to resolve, even after a third test, because there is no true gold-standard assay for chronic T. Details on family history, potential exposure to the vector, and history of blood transfusion in endemic areas should be recorded. A detailed review of systems should focus on cardiovascular and gastrointestinal symptoms (Table 103. Screening should be offered to other family members, including children of seropositive mothers, and the patient should be advised regarding possible transmission routes (such as blood and organ donation).

The most commonly identified risk factors relate to water-borne transmission arteria circumflexa scapulae buy cheap inderal 40 mg, including backpacking blood pressure medication icu proven inderal 40 mg, recreational water use arrhythmia babys heartbeat inderal 40 mg order otc, or having a shallow well for drinking water hypertension quality measures inderal 80 mg lowest price. Occasional large outbreaks due to contaminated water have been identified heart attack at 30 generic inderal 80 mg, including a recent outbreak of over 3000 symptomatic cases in a Norwegian city. The seasonality of infections in the United States with increased occurrence in the summer and early fall probably reflects the increased use of recreational water facilities. The increased incidence in children who attend daycare facilities reflects direct fecal­oral transmission, and the increased incidence in homosexual men most likely results from oral­anal sexual contact. Although less common than water-borne transmission, food-borne transmission has also been documented. The cyst is oval in shape and approximately 8 by 12 µm in size and contains four nuclei that can be visualized microscopically. The cyst is environmentally resistant, and as few as 10 cysts can initiate infection after ingestion. After passage through the stomach, the cyst excysts to produce two binucleate trophozoites that are pear-shaped and approximately 10 to 12 µm in length by 5 to 7 µm in width. When the trophozoites detach from the intestinal wall, an imprint displays the site of their attachment. The trophozoites replicate by binary fission, and some of these trophozoites encyst after exposure to bile or as a result of cholesterol starvation and are passed in the feces to continue the cycle of infection. In addition, there is some evidence for differences in pathogenicity among different isolates. B differs by nearly 20% from both, suggesting that it may properly be considered a different species. Interestingly, some studies correlating symptoms with genotype have found that genotype B infections are more frequently symptomatic, whereas others have found that symptoms are more associated with genotype A2. Patients with symptomatic disease have villous shortening, which can range from mild to severe, both from one patient to another and even within the same patient. There is no evidence for toxin-mediated diarrhea and mucosal invasion has not been convincingly shown. Therefore much of the recent interest has focused on an immunopathogenic mechanism for the diarrhea. Animal models8 and human observations9 have shown epithelial cell dysfunction and impairment of the barrier function, likely involving intraepithelial lymphocytes. The onset of giardiasis can be relatively indolent, and frequently patients do not present for evaluation early; therefore giardiasis should be considered seriously in patients with at least 5 to 7 days of diarrhea. In contrast, most diarrhea caused by viral and bacterial pathogens resolves within 3 to 5 days. The differential diagnosis includes those illnesses that present with sub-acute or chronic diarrhea of a small intestinal source. The fluid and electrolyte loss caused by some small intestinal pathogens is distinctly uncommon with giardiasis. Thus the list of pathogens that could produce diarrhea mimicking giardiasis is short but could include atypical presentations of Campylobacter or Salmonella infections. Both celiac disease and tropical sprue present with chronic diarrhea that may be accompanied by weight loss. Giardiasis typically has a more readily defined onset of symptoms than celiac disease or tropical sprue. Celiac disease may be a more common cause of diarrhea in the United States but is much less common in many developing regions, so a travel and exposure history is important. Lactose intolerance is a common cause of chronic diarrhea but does not cause weight loss and resolves with elimination of lactose from the diet. Irritable bowel syndrome frequently presents with chronic diarrhea but does not cause weight loss; as noted later, it is particularly common after an episode of giardiasis. The initial diagnostic test when giardiasis is considered is a microscopic examination of a concentrated fecal specimen for cysts or trophozoites. Cysts are much more commonly found than trophozoites and can be identified equally well from fresh or preserved specimens. In contrast, freshly collected specimens are required for the identification of trophozoites. The daily stool volume is typically normal, and one to several stools daily is usual. The diarrhea is frequently accompanied by abdominal pain, bloating, flatulence, and malabsorption with weight loss (see Table 95. Fever is uncommon, and when present, it is found early and resolves within a few days. Bloody diarrhea and systemic toxicity are not seen with giardiasis and should raise the suspicion for invasive bacterial infections or amebiasis. The physical examination is typically normal or demonstrates non-specific abnormalities. Mild abdominal tenderness may be present, but severe tenderness should suggest an alternative diagnosis. Likewise, significant fluid loss is uncommon with giardiasis, so evidence of dehydration on examination or by laboratory testing should prompt a search for alternative diagnoses. The major focus in nucleic acid testing has been in multiplex tests, some of which are limited to parasites and others that include parasites, bacteria, and viruses. Alternatively, several commercial Giardia cyst antigen tests are available, all of which detect cyst antigens in fecal samples, either by immunoassay or by immunofluorescence or chromatographic detection (Table 95. These are more sensitive than conventional microscopy, such that a single test can suffice. The sensitivity of the immunoassay tests is in the 93% to 100% range and the fluorescent antibody test near 100% but with the caveat that there is not an adequate gold standard for a validation of the diagnosis, so these numbers should be taken with caution. The specificity of the tests is in the 98% to 99% range, so there should be few false-positive results in populations with a high prevalence. One limitation of these antigen-based tests is that they detect cysts but not trophozoites. However, the enzyme immunoassay is less labor-intensive and does not require the availability of a fluorescent microscope. For some patients with giardiasis, fecal examinations are repeatedly negative, but Giardia trophozoites can be detected in the duodenum by endoscopy or by the string test. The string test involves the patient swallowing a capsule on the end of a string, pulling it out after 4 hours to overnight, and then examining the end microscopically for the presence of trophozoites. In clinical practice, it is very common to empirically treat for giardiasis in patients who have a clinical presentation consistent with giardiasis, especially in resource-poor areas. Initial concerns regarding metronidazole in pregnancy have been allayed, at least for the second and third trimesters, by extensive experience with treating bacterial vaginosis. Nausea and a metallic taste are common and potentially treatment-limiting side effects. These drugs also have a disulfiram-like activity after ethanol ingestion, so alcohol use during treatment is prohibited. Single doses and short courses of therapy with metronidazole have had high failure rates, so treatment should be continued for 5 to 10 days, whereas tinidazole demonstrates excellent efficacy with single-dose therapy, which may make it the preferred agent in many settings. Secnidazole and ornidazole are other nitroimidazoles that have excellent efficacy with single-dose treatment courses but are not available in the United States. Albendazole is an anti-helminthic agent that inhibits tubulin and has activity against giardiasis. In addition, its broad antihelminthic activity may be an advantage in settings with a high prevalence of intestinal helminth infections. However, single-dose therapy has demonstrated poor efficacy for the treatment of giardiasis, so treatment courses of 5 days are used. Quinacrine has excellent efficacy and at one time was the drug of choice in the United States, but has been largely replaced by the nitroimidazoles, partly because of nausea and vomiting and occasional reports of psychosis. Nitazoxanide has activity for Giardia and Cryptosporidium as well as other microbes and has been approved for use in the United States. It has been studied in children using 3-day courses, yielding response rates of about 70% to 80%, and has been well tolerated. Furazolidone became popular for treating giardiasis in children because it is tolerated better than quinacrine and is available in liquid suspension. However, compliance is more difficult than with some drugs, because it is administered four times daily for 7 to 10 days. Paromomycin has been evaluated in a few earlier studies, demonstrating an efficacy of about 55% to 90%. Persistent symptoms after treatment of giardiasis are common and usually do not represent continued infection. Quinacrine is no longer generally available in the United States but can be obtained from a compounding pharmacy. Persistent gastrointestinal symptoms are common after treatment of several other intestinal pathogens as well. A negative test in someone with persistent diarrhea but no weight loss suggests post-infectious irritable bowel disease or perhaps lactose intolerance. However, with a negative fecal examination in the setting of weight loss, upper endoscopy should be considered to identify other diagnoses such as gluten enteropathy. For patients with documented relapse after treatment, retreatment is usually effective. In addition, relapses may be more common in the setting of immunoglobulin deficiency, so immunoglobulin levels should be determined. Patients who fail re-treatment with a standard course of a nitroimidazole usually respond to subsequent treatment with metronidazole in addition to either albendazole or quinacrine. Contaminated hands are the source of Giardia in the setting of daycare or food; therefore handwashing should be employed. The identification of a new Giardia duodenalis assemblage in marine vertebrates and a preliminary analysis of G. Rapid reinfection by Giardia lamblia after treatment in a hyperendemic third world community. Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum. A communitywide outbreak of giardiasis with evidence of transmission by a municipal water supply. A metaanalysis of the efficacy of albendazole compared with tinidazole as treatments for Giardia infections in children. The importance of this infection was illustrated by landmark studies conducted in the 1990s in West Africa which showed that children with a clinical episode of cryptosporidiosis subsequently suffered higher rates of death, with an excess mortality 2. Cryptosporidiosisaffected children may have impaired growth and cognitive function2 and have multiple symptomatic episodes before they acquire partial protective immunity. Transmission has also been linked to international travel, contact with animals or children with diarrhea, recreational water exposure, and multiple sexual partners or anal intercourse. Testing for this parasite should always be considered in immunocompromised people with diarrhea. The infectious dose is low (10­1000 oocysts); in animal models a single oocyst can cause infection. Internal autoinfection is common and likely to be responsible for the chronic nature of the disease in immunocompromised people. Transient infection may be asymptomatic or symptomatic with diarrhea, which is most severe in young children. Disease resolution depends on intact cell-mediated immunity, and the antibody response appears to be nearly irrelevant. It is a classic diarrheal "emerging disease" because it has a very low infectious dose, is most severe in immunocompromised populations, is highly resistant to anti-parasitic therapy, has human and non-human reservoirs, and can cause major epidemics when public health measures break down. Cryptosporidiosis is most common in developing countries but remains a significant pathogen of children and the elderly in industrialized nations, with water-borne, foodborne, person-to-person, and zoonotic transmission pathways. Sporozoites released by oocysts go through several rounds of multiplications in the small intestine and colon, and sporulated oocysts are generated and excreted by infected persons or animals. Oocysts are infective upon excretion, thus permitting direct and immediate fecal­oral transmission. Cryptosporidium parasites infect the colonic mucosa and, less commonly, the small intestine and stomach. Replicating parasites may, however, infect the entire gut from oropharynx to anus. This may account for its resistance to therapeutic drugs that are effective against similar parasites (such as malaria, Toxoplasma, or Babesia), which are intracellular but intracytoplasmic. It is located on the apical surface of the intestinal cell; host cell membranes can be seen enveloping the globular parasite. At the base of the parasite, an electron-thick membrane can be seen separating the intracellular parasite from the host cell cytoplasm. Immune competence is an important determinant in the severity and duration of intestinal disease in humans. First infections are usually symptomatic with watery diarrhea, vomiting, nausea, abdominal cramps, and fatigue. Both low-grade fever and cough are more frequently found than in most other enteric infections. In developing countries where repeated exposure is common, most infected children are asymptomatic. Cryptosporidiosis is more common in malnourished children and those with persistent diarrhea. Both asymptomatic and symptomatic cryptosporidiosis appear to cause malnutrition, stunted growth, and impaired cognitive function.

Inderal 40 mg fast delivery. OMRON EVOLV Tubeless Wireless Upper Arm Blood Pressure Monitor Quick Start Guide.

References

• Ma, J., Nishimura, H., Fogo, A., Kon, V., Inagami, T., Ichikawa, I. Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction Rapid Communication. Kidney Int. 1998;53:937-944.
• Butler RJ, Robinson JC: Alarm treatment for childhood nocturnal enuresis: an investigation of within-treatment variables, Scand J Urol Nephrol 36(4):268n272, 2002.
• Kaplan BS, Fay FM, Shah VM, et al: Autosomal recessive polycystic kidney disease, Pediatr Nephrol 3:43n49, 1989. Kaplan BS, Kaplan P, Rosenberg HK, et al: Polycystic kidney disease in childhood, J Pediatr 115:867, 1989. Karmazyn B, Tawadros A, Delaney LR, et al: Ultrasound classification of solitary renal cysts in children, J Pediatr Urol 11:149e1, 2015.
• Ryan T, Vasey CG, Presti CF, et al: Exercise echocardiography: Detection of coronary artery disease in patients with normal left ventricular wall motion at rest. J Am Coll Cardiol 1988;11:993-999.
• Brickfield FX, Carter WH, Johnson RE. Erythromycin in the treatment of acute bronchitis in a community practice. J Fam Pract 1986; 23: 119-122.
• Seung KB, Park DW, Kim YH, et al. Stents versus coronary artery bypass grafting for left main coronary artery disease. N Engl J Med. 2008;358:1781-92.
• Vijayalakshmi IB. 'Role of Echocardiography in Rarest Congenital Heart Disease' in Journal of Indian Academy of Echocardiography. 2003;7:509-12.
• Shih DQ, Kwan LY. All roads lead to Rome: update on Rome III criteria and new treatment options. Gastroenterol Rep 2007;1(2):56-65.